Estimated market cap $320.09MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Aug 7, 2026, last close Nov 13, 2026.29.13M shares, shares as of Aug 7, 2026CIK 1177648The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 9 sells
$183.2K sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Enanta Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Enanta Pharmaceuticals, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
H-1B labor applications at Enanta Pharmaceuticals, Inc.
2 certified in 12 mo
Labor condition applications decided by the Department of Labor, matched to Enanta Pharmaceuticals, Inc. by employer name. An application is not a hire.
Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —The wage the employer offered, as filed, with its unit. The yearly figure restates it per year (hourly x 2,080, weekly x 52, every two weeks x 26, monthly x 12) from the low end of the offered range. It is not what the worker was paid.
H-1B labor applications decided at Enanta Pharmaceuticals, Inc. by quarter
Quarter
Certified
All decided
Workers asked for
2024 Q3
1
1
1
2024 Q4
0
0
0
2025 Q1
0
0
0
2025 Q2
1
1
1
2025 Q3
0
0
0
2025 Q4
0
0
0
2026 Q1
1
1
1
2026 Q2
1
1
1
Most common job titles at Enanta Pharmaceuticals, Inc.
We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
78
43.8% of shares · 21 added
Latest 10-Q
Q2 2026
What changed in Enanta Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.
Filed Aug 12, 2026 · Quarter ended Jun 30, 2026
AI No AI summary for this 10-Q: management's discussion could not be compared, and the other sections did not change.
Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: risk factors and legal proceedings.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Dec 5, 2025. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
78 funds report ENTA. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 94% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 27.25M reported shares by 29.13M shares, from the company’s SEC filing as of Aug 7, 2026.
122 funds hold the stock.
Q3 2026: 44% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202586%
Q3 202566%
Q4 202591%
Q1 202692%
Q2 202694%
Q3 2026 (so far)44%
Q3 2026. 12 new, 21 added to, 29 trimmed, 56 exited since Q2 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds ENTA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Enanta Pharmaceuticals, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
39
—
3.30M
$58.4M
Q3 2013
52
+13
3.76M
$86.0M
Q4 2013
67
+15
4.81M
$131.7M
Q1 2014
81
+14
8.44M
$337.2M
Q2 2014
98
+17
9.76M
$420.2M
Q3 2014
110
+12
11.25M
$445.2M
Q4 2014
124
+14
10.82M
$552.0M
Q1 2015
118
-6
12.42M
$380.0M
Q2 2015
132
+14
13.83M
$621.6M
Q3 2015
145
+13
16.02M
$592.8M
Q4 2015
137
-8
14.63M
$483.1M
Q1 2016
152
+15
14.24M
$418.1M
Q2 2016
130
-22
13.43M
$296.2M
Q3 2016
134
+4
13.08M
$348.1M
Q4 2016
149
+15
13.39M
$448.3M
Q1 2017
126
-23
12.88M
$396.9M
Q2 2017
122
-4
12.61M
$453.9M
Q3 2017
127
+5
12.78M
$598.0M
Q4 2017
148
+21
14.04M
$823.9M
Q1 2018
181
+33
14.74M
$1.2B
Q2 2018
193
+12
15.12M
$1.8B
Q3 2018
197
+4
16.84M
$1.4B
Q4 2018
183
-14
17.05M
$1.2B
Q1 2019
194
+11
18.17M
$1.7B
Q2 2019
194
0
17.78M
$1.5B
Q3 2019
176
-18
17.91M
$1.1B
Q4 2019
171
-5
18.64M
$1.2B
Q1 2020
155
-16
18.06M
$929.6M
Q2 2020
180
+25
18.28M
$917.5M
Q3 2020
172
-8
18.84M
$862.3M
Q4 2020
151
-21
19.35M
$814.9M
Q1 2021
150
-1
19.43M
$956.7M
Q2 2021
152
+2
18.89M
$831.4M
Q3 2021
149
-3
19.40M
$1.1B
Q4 2021
181
+32
18.85M
$1.4B
Q1 2022
169
-12
19.67M
$1.4B
Q2 2022
155
-14
20.23M
$956.3M
Q3 2022
160
+5
19.72M
$1.0B
Q4 2022
147
-13
19.23M
$894.5M
Q1 2023
145
-2
20.05M
$811.4M
Q2 2023
134
-11
20.23M
$438.4M
Q3 2023
133
-1
20.14M
$225.0M
Q4 2023
106
-27
21.35M
$200.9M
Q1 2024
108
+2
26.64M
$465.3M
Q2 2024
101
-7
22.29M
$289.1M
Q3 2024
112
+11
21.47M
$222.5M
Q4 2024
108
-4
19.91M
$114.5M
Q1 2025
110
+2
18.63M
$102.8M
Q2 2025
108
-2
18.45M
$139.4M
Q3 2025
122
+14
19.12M
$228.6M
Q4 2025
132
+10
26.39M
$416.1M
Q1 2026
133
+1
26.77M
$338.1M
Q2 2026
122
-11
27.25M
$397.2M
Q3 2026
78
-44
12.76M
$168.0M
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (29251M106). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.